Log in
NASDAQ:DXCM

DexCom Stock Forecast, Price & News

$318.21
+5.66 (+1.81 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$312.01
Now: $318.21
$319.66
50-Day Range
$312.00
MA: $358.86
$418.00
52-Week Range
$182.07
Now: $318.21
$456.23
Volume586,123 shs
Average Volume1.25 million shs
Market Capitalization$30.56 billion
P/E Ratio131.49
Dividend YieldN/A
Beta0.96
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; and a collaboration with Companion Medical, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Read More
DexCom logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.05 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:DXCM
CUSIP25213110
Phone858-200-0200
Employees3,900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.48 billion
Cash Flow$2.24 per share
Book Value$15.61 per share

Profitability

Net Income$101.10 million

Miscellaneous

Market Cap$30.56 billion
Next Earnings Date2/11/2021 (Estimated)
OptionableOptionable
$318.21
+5.66 (+1.81 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DXCM News and Ratings via Email

Sign-up to receive the latest news and ratings for DXCM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











DexCom (NASDAQ:DXCM) Frequently Asked Questions

How has DexCom's stock price been impacted by Coronavirus?

DexCom's stock was trading at $252.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, DXCM shares have increased by 26.1% and is now trading at $318.21.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of DexCom?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 1 sell rating, 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for DexCom
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than DexCom?

Wall Street analysts have given DexCom a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but DexCom wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is DexCom's next earnings date?

DexCom is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for DexCom
.

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) announced its quarterly earnings data on Tuesday, October, 27th. The medical device company reported $0.94 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.64 by $0.30. DexCom had a net margin of 12.69% and a return on equity of 27.29%.
View DexCom's earnings history
.

What guidance has DexCom issued on next quarter's earnings?

DexCom issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, October, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.9-1.9 billion, compared to the consensus revenue estimate of $1.87 billion.

What price target have analysts set for DXCM?

19 analysts have issued 1 year price objectives for DexCom's shares. Their forecasts range from $230.00 to $500.00. On average, they anticipate DexCom's stock price to reach $406.22 in the next year. This suggests a possible upside of 27.7% from the stock's current price.
View analysts' price targets for DexCom
.

Are investors shorting DexCom?

DexCom saw a drop in short interest in the month of October. As of October 30th, there was short interest totaling 2,740,000 shares, a drop of 31.0% from the October 15th total of 3,970,000 shares. Based on an average trading volume of 948,900 shares, the short-interest ratio is presently 2.9 days.
View DexCom's Short Interest
.

Who are some of DexCom's key competitors?

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), salesforce.com (CRM), ServiceNow (NOW), The Walt Disney (DIS), The Trade Desk (TTD) and Shopify (SHOP).

Who are DexCom's key executives?

DexCom's management team includes the following people:
  • Mr. Kevin R. Sayer, Exec. Chairman, CEO & Pres (Age 62, Pay $2.09M)
  • Mr. Quentin S. Blackford, CFO & COO (Age 41, Pay $1.17M)
  • Mr. Steven R. Pacelli, Exec. VP of Strategy & Corp. Devel. (Age 48, Pay $873.62k)
  • Mr. Andrew K. Balo, Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel. (Age 72, Pay $875.97k)
  • Mr. Richard B. Doubleday, Exec. VP & Chief Commercial Officer (Age 57, Pay $930.08k)
  • Mr. Jereme Sylvain, Sr. VP of Fin., Chief Accounting Officer & Corp. Controller (Age 40)
  • Mr. Jacob Steven Leach, Exec. VP & CTO (Age 42)
  • Mr. Sean Christensen, Sr. Investor Relations Mang.
  • Mr. Patrick Michael Murphy, Exec. VP & Chief Legal Officer (Age 41)
  • Mr. Jeffrey C. Moy, Exec. VP of Operations (Age 60)

What is DexCom's stock symbol?

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

Who are DexCom's major shareholders?

DexCom's stock is owned by many different retail and institutional investors. Top institutional investors include Morgan Stanley (4.29%), Jennison Associates LLC (2.85%), Sands Capital Management LLC (2.43%), Blair William & Co. IL (1.09%), Nuveen Asset Management LLC (0.84%) and Great West Life Assurance Co. Can (0.69%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman and Steven Robert Pacelli.
View institutional ownership trends for DexCom
.

Which institutional investors are selling DexCom stock?

DXCM stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Sei Investments Co., First Hawaiian Bank, Columbus Circle Investors, First Trust Advisors LP, Cubist Systematic Strategies LLC, Dowling & Yahnke LLC, and Massachusetts Financial Services Co. MA. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman, and Steven Robert Pacelli.
View insider buying and selling activity for DexCom
.

Which institutional investors are buying DexCom stock?

DXCM stock was acquired by a variety of institutional investors in the last quarter, including Great West Life Assurance Co. Can, Sands Capital Management LLC, Point72 Asset Management L.P., Nuveen Asset Management LLC, Jackson Square Partners LLC, Worldquant Millennium Advisors LLC, Charles Schwab Investment Management Inc., and BP PLC.
View insider buying and selling activity for DexCom
.

How do I buy shares of DexCom?

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is DexCom's stock price today?

One share of DXCM stock can currently be purchased for approximately $318.21.

How big of a company is DexCom?

DexCom has a market capitalization of $30.56 billion and generates $1.48 billion in revenue each year. The medical device company earns $101.10 million in net income (profit) each year or $1.84 on an earnings per share basis. DexCom employs 3,900 workers across the globe.

What is DexCom's official website?

The official website for DexCom is www.dexcom.com.

How can I contact DexCom?

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]

This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.